Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337795 | 0.86 | GCGR (0.38) | PTGS2PTGS1 | |
| SCHEMBL2343663 | 0.86 | PTGS2 (0.37) | ADORA2AADORA1PTGS2PTGS1 | |
| SCHEMBL2344282 | 0.85 | ADORA1 (0.43) | ADORA1SCN9APTGS2PTGS1ADORA2B | |
| SCHEMBL2344730 | 0.84 | PTGS2 (0.37) | ADORA1SCN9APTGS2PTGS1 | |
| SCHEMBL2342269 | 0.81 | HMGCR (0.51) | PTGS2PTGS1 | |
| SCHEMBL2344244 | 0.79 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL27455717 | 0.77 | ADORA2A (0.39) | ADORA2AADORA1SCN9AADORA2BKDM4E | |
| SCHEMBL6082682 | 0.72 | ADORA2A (0.44) | ADORA2AADORA1SCN9AADORA2BHRH2 | |
| SCHEMBL2343909 | 0.71 | ADORA2A (0.45) | ADORA2AADORA1SCN9AADORA2BHRH2 | |
| SCHEMBL2342292 | 0.71 | ADORA2A (0.45) | ADORA2AADORA1SCN9AADORA2BHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | claimed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | claimed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | claimed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| US-8034932-B2 | Hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitor; anticholesterol agents;dyslipidemia; chemical intermediate for rosuvastatin | ASTRAZENECA UK LIMITED (GB) | 2011-10-11 | — | — | US | disclosed |
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207903-A1 | Chemical Process | CYP2C9, CYP2B6, CYP7A1 | ADORA2A 4749/4885ADORA1 4310/4885SCN9A 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.